Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma
Journal of Immunotherapy and Precision Oncology · 01.02.2024 · 7 (1) · 67-72
DOI: 10.36401/jipo-23-19 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Immunotherapy and Precision Oncology, online erschienen am 05.02.2024. Verfasst von Harriet Herbison und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Monash Health, Clayton, Victoria, Australia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
NUT carcinomas (NCs) are a group of rare tumors that can occur anywhere in the body and are defined by the fusion of the nuclear protein in testis (NUTM1) resulting in increased transcription of proto-oncogenes. NCs have a poor prognosis that varies according to the site of origin with an urgent need to develop new treatment strategies. Case reports on immunotherapy in pulmonary NC have been published, and bromodomain and extraterminal (BET) inhibitors have shown activity in NC in phase I/II trials. We present the case of a 27-year-old woman with an unresectable sinonasal NC who had a sustained clinical response to both immunotherapy and BET inhibitor therapy. This is the first reported case of immunotherapy in sinonasal NC, and it highlights the different responses to a range of treatments including BET inhibitor therapy. This case supports the theory that NCs arising from different primary sites have differing prognoses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Monash Health, Clayton, Victoria, Australia.
- Department of Radiation Oncology, The Alfred Hospital, Melbourne, Victoria, Australia.
- Department of Anatomical Pathology, Cabrini Pathology, Melbourne, Victoria, Australia.
- Department of Medical Oncology, The Alfred Hospital, Melbourne, Victoria, Australia.
- Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Zitieren
APA
Herbison, H., Davis, S., Nickless, D., Haydon, A., & Ameratunga, M. (2024). Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma. Journal of Immunotherapy and Precision Oncology, 7(1), 67-72. https://doi.org/10.36401/jipo-23-19
Vancouver
Herbison H, Davis S, Nickless D, Haydon A, Ameratunga M. Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma. Journal of Immunotherapy and Precision Oncology. 2024;7(1):67-72. doi:10.36401/jipo-23-19
BibTeX
@article{Herbison2024,
author = {Herbison, Harriet and Davis, Sidney and Nickless, David and Haydon, Andrew and Ameratunga, Malaka},
title = {Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma},
journal = {Journal of Immunotherapy and Precision Oncology},
year = {2024},
volume = {7},
number = {1},
pages = {67--72},
doi = {10.36401/jipo-23-19}
}
EUVIMED